Serina Therapeutics financials
$2.08+3.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $130.0K | $56.0K |
| Gross profit | $130.0K | $56.0K |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$24.0M | -$17.0M |
| Net income | -$19.4M | -$11.1M |
| Net margin | −14950.8% | −19894.6% |
| Diluted EPS | $-1.91 | $-1.51 |
| EBITDA | -$23.9M | -$16.9M |
| Operating cash flow | -$18.0M | -$17.1M |
| Free cash flow | -$18.0M | -$17.2M |
| Diluted shares | 10.2M | 7.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $3.1M | $3.7M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $2.9M | $0.00 |
| Total assets | $7.0M | $6.7M |
| Total liabilities | $7.0M | $6.2M |
| Shareholders' equity | -$37.0K | $508.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology